Osteopore

Osteopore EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Osteopore (OSX.AX) as of Nov 14, 2026 is -1.52. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -1.62 — a change of -6.06% (higher).

EV/FCF

-1.52

YoY

-6.06%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Osteopore is 2025 -1.52 . EV/FCF (Enterprise Value to Free Cash Flow) of Osteopore was 2024 -1.62 . It decreases by -6.06% higher compared to the previous year.

The Osteopore EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-0.05 AUD
Jan 1, 2019
-0.90 AUD
Jan 1, 2020
1.98 AUD
Jan 1, 2021
0.16 AUD
Jan 1, 2022
-0.55 AUD
Jan 1, 2023
-1.14 AUD
Jan 1, 2024
-1.62 AUD
Jan 1, 2025
-1.52 AUD
The Osteopore EV/FCF history
YEAREV/FCFYoY
-1.52-6.06%
-1.62+42.03%
-1.14+106.08%
-0.55-445.91%
0.16-91.90%
1.98-319.80%
-0.90+1,707.29%
-0.05-99.96%
-126.72+622.55%
-17.54—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Osteopore Stock analysis

What does Osteopore do? Osteopore Ltd. develops and markets bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgeries. The company commercializes bespoke products engineered to facilitate bone healing, utilizing patented technology that fabricates micro-structured scaffolds through 3D printing and bioresorbable materials. Key products include Osteoplug in plug and strip configurations for craniotomy gap filling, Osteomesh, and Osteoplug-C for craniofacial applications. These solutions support bone tissue integration from the skull to the bone flap, targeting procedures such as cranioplasty, craniosynostosis, and guided bone regeneration. The company serves medical professionals and healthcare facilities requiring advanced bone regeneration solutions. Its products are designed for specific surgical applications including craniotomy, orbital floor reconstruction, socket preservation, and minimally invasive skull base surgery. Osteopore Ltd. focuses on delivering patient-specific implants (PSI) for cranial and mandibular procedures, alongside solutions for burr hole restoration with shunt drainage systems. These offerings cater to specialized surgical segments demanding precision and biocompatibility. Osteopore Ltd.'s revenue streams derive from the sale of its proprietary implant systems to hospitals and surgical centers. The company’s technology enables the production of custom implants that address complex bone healing needs, particularly in neurosurgery, orthopaedics, and maxillofacial procedures. By providing tailored solutions for cranioplasty, craniosynostosis, and guided bone regeneration, the company meets the demands of healthcare providers seeking effective bone regeneration technologies. Osteopore is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Osteopore stock

EV/FCF (Enterprise Value to Free Cash Flow) of Osteopore is -1.52 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Osteopore changed from -1.62 to -1.52, representing a -6.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Osteopore since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Osteopore with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Osteopore

All Key Metrics — Osteopore